Horizon Discovery

Horizon will develop NTRK fusion immunohistochemistry reference standards to be used in oncology assays.

Expanding the companies' pre-existing agreement will allow Horizon to use CRISPR in new products and services.

The investment bank began coverage with an Outperform rating, noting that Horizon's recent acquisition of Dharmacon is highly complementary and synergistic.

Stakeholders increasingly highlight the need for better, more standardized tools to validate and compare liquid biopsy tests, and commercial firms have responded.

The technology is based on helitrons, a type of eukaryotic transposon that can incorporate multiple copies of a DNA sequence into a genome.

The deal covers Atum's custom vectors and Horizon's CHO Source biomanufacturing platform.

The firm has secured rights to use CRISPR in cell lines for biomanufacturing and will work with Solentim to increase editing throughput while decreasing costs.

The partnership aims to improve cancer molecular profiling by combining Horizon's HDx reference standards with Sophia's artificial intelligence solution.

Horizon will supply cell-free DNA-based molecular reference standards for inclusion in CareDx’s cfDNA testing workflows for the monitoring of transplanted organ rejection.

Horizon Discovery, Desktop Genetics, and Vectalys will work together to create fully-licensed, customizable kits for CRISPR/Cas9-based genetic screening.

Pages

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.